Everolimus improves behavioral deficits in a patient with autism associated with tuberous sclerosis: a case report by unknown
Ishii et al. Neuropsychiatric Electrophysiology  (2015) 1:6 
DOI 10.1186/s40810-015-0004-xCASE REPORT Open AccessEverolimus improves behavioral deficits in a
patient with autism associated with tuberous
sclerosis: a case report
Ryouhei Ishii1*, Mari Wataya-Kaneda2, Leonides Canuet3, Norio Nonomura4, Yasutomo Nakai4
and Masatoshi Takeda1* Correspondence:
ishii@psy.med.osaka-u.ac.jp
1Department of Psychiatry,
Graduate School of Medicine, Osaka
University, D3 2-2 Yamada-okaSuita,
Osaka 565-0871, Japan
Full list of author information is
available at the end of the articleAbstract
Neuropsychiatric symptoms are very common in tuberous sclerosis complex (TSC).
Autism is present in up to 60% of these patients, and TSC accounts for 1-4% of all
cases of autism. In this study, we illustrate a 27 year-old female patient with TSC, autism,
and renal angiomyolipomas, in whom everolimus treatment was associated with
improvement in behavioral deficits. She took part in an everolimus clinical trial (EXIST-2:
ClinicalTrials.gov number NCT00790400) to assess the efficacy of this drug in TSC. It was
a randomized, double-blind, placebo-controlled study of everolimus (RAD001) (10 mg/
day during 18 months) in the treatment of TSC-related angiomyolipoma. The Japanese
version of the Aberrant Behavior Checklist (ABC) and the Pervasive Developmental
Disorders - Autism Society Japan Rating Scale (PARS) were used to assess the
severity of behavioral deficits. Clinical improvement after everolimus treatment was
more remarkable for irritability, stereotypic behavior and inappropriate speech scores
on the ABC scale. In addition, stereotypic behavior and lethargy/social withdrawal
subscale scores showed an overall reduction of 10 and 8 points, respectively. The
severity of autistic symptoms measured with the PARS also showed a marked reduction
after treatment. There were no abnormal EEG findings before the treatment and no
changes after the treatment. Our findings are consistent with those of animal models
proposing that treatment of TSC1 and TSC2 mutant mice with the mTOR inhibitor
rapamycin, reversed impaired social interaction. This makes everolimus a promising
drug for the treatment of TSC patients with autism. Our findings warrant further
investigation in future clinical trials.
Keywords: The mammalian target of rapamycin (mTOR), Everolimus, Autism,
Tuberous sclerosis, EEG, EXIST-2Background
Tuberous sclerosis complex (TSC) is a neurocutaneous disorder caused by mutations
in either of the two tumor suppressor genes TSC1 or TSC2, encoding hamartin and
tuberin, respectively (van Slegtenhorst et al, 1997; European Chromosome 16 Tuberous
Sclerosis Consortium, 1993). Typical TSC lesions include hypomelanic macules and facial
angiofibromas, as well as brain cortical tubers, subependymal nodules, and subependymal
giant cell astrocytomas (SEGAs) (Holmes et al, 2007; Curatolo et al, 2008; Sahin, 2012).
In addition to manifestations in the skin and nervous system, TSC is associated with© 2015 Ishii et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
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gioleiomyomatosis, and rhabdomyomas (Crino et al, 2006; Curatolo et al, 2008; Orlova
and Crino, 2010; Ehninger, 2013).
Neuropsychiatric symptoms are very common in TSC, including epilepsy and a broad
range of cognitive and behavioral problems (Kopp et al, 2008). It is estimated that ap-
proximately 70 to 90% of all TSC patients have seizures at some point during their life
(Holmes et al, 2007; Ess, 2010; Sahin, 2012). West syndrome (infantile spasms) is the
commonest epileptic disorder, which is associated with more intellectual disability and
a less favorable neurological outcome (Joinson et al, 2003). This syndrome is seen in up
to 50% of children with TSC (Ess, 2010).
Autism is a heterogeneous neurodevelopmental disorder with onset in early child-
hood, characterized by impairments in communication, reciprocal social interaction,
and restricted and stereotyped patterns of interests and activities (Curatolo et al, 2004).
Autism spectrum disorders (ASD) are frequently diagnosed in patients with TSC. Autism
may be present in up to 60% of these patients, and TSC accounts for 1 to 4% of all cases
of autism (Fombonne, 2003; Curatolo et al, 2004; Ehninger, 2013). In fact, the incidence of
autism in patients with TSC may be higher than that of cardiac and renal abnormalities,
for which screening is routinely conducted (Curatolo et al, 2004). Although the majority
of TSC individuals with autism have a history of infantile spasms, there are also subjects
who develop autism but with no history of seizures (Numis et al., 2011), suggesting that
additional factors also play a role in this association.
To date, the treatment of TSC is entirely symptomatic, targeting. A recent review by
Ehninger (2013) highlights that currently available therapies do not treat the cause of
TSC symptoms but rather use general pharmacological and behavioral approaches to
manage specific sets of symptoms, such as seizures, attention deficit hyperactivity dis-
order, (ADHD), anxiety, and depression, etc. However, no treatments are currently
available to target neurocognitive dysfunction associated with this disorder. It has been
demonstrated that hamartin and tuberin bind together to form a biochemical complex
that inhibits the mammalian target of rapamycin (mTOR) that controls translation,
proliferation, and cell growth (Curatolo et al, 2010). The discovery that the products of
the TSC genes regulate mTOR signaling (Tee et al., 2002) has paved the way to current
experimental mTORC inhibitor-based treatment approaches. Although the dysregula-
tion of intracellular signaling through the activation of mTOR pathway is thought to
contribute to the pathogenesis of epilepsy, cognitive dysfunction and behavioral abnor-
malities in TSC, most studies on mTOR inhibition therapy in humans have focused on
seizure control and tumor growth reduction.
Clinical trials in TSC populations using everolimus (RAD001, Novartis), as mTOR in-
hibitor, have shown promising results regarding epilepsy, skin manifestations, subepen-
dymal giant cell astrocytomas (SEGAs), and renal and lung manifestations (Bissler
et al., 2008) and also improved subependymal giant cell astrocytomas (SEGAs), specific
brain tumors associated with TSC (Krueger et al, 2010; Józwiak et al 2012; Curran et al
2012; Franz et al, 2013). In fact, everolimus has already been approved to treat this kind
of TSC lesions (Kohrman, 2012).
Preclinical studies in animal models of TSC, however, have assessed the potential
efficacy of mTOR-based treatment on TSC-related cognitive impairments. In adult
mice with a heterozygous, inactivating mutation in the TSC2 gene, mTOR inhibition
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emerged in the absence of neuropathology and seizures (Ehninger et al. 2008, 2009). A
recent study by Sato et al. (2012) in TSC mutant adult mice found that impaired social
behavior also reversed by mTOR inhibitor treatment, which associated with mTOR in-
hibition at the molecular level. Others have also provided evidence that autistic-like
behavior can be prevented with mTOR treatment in mouse models of TSC (Tsai et al,
2012; Talos et al, 2012; Reith et al. 2013). Altogether, these results propose that consid-
erable therapeutic opportunities may exist for neuropsychiatric impairments associated
with TSC, even if treatment is initiated in adulthood.
In humans, the effects of mTOR inhibitors on neurocognitive function and autistic
phenotypes have rarely been explored. Thus, it is unknown whether mTOR inhibition
can improve autistic features in individuals with TSC. An open label trial of rapamycin
for angiomyolipomas and lymphangiomyomatosis reported certain improvement in
neurocognitive function, particularly in recall memory in patients with TSC (Davies et
al 2011). A placebo-controlled double blind trial of everolimus in patients with TSC
and neurocognitive deficits is currently underway (ClinicalTrials.gov; NCT01289912).
This study is enrolling individuals with TSC between the ages of 6 and 21 years, with
IQ greater than or equal to 60, who are stable on an anti-seizure medication regimen
and have no evidence of SEGAs. The primary endpoint is improvement in neurocogni-
tive tests while autism, seizure frequency, and sleep habits are evaluated as secondary
endpoints (Sahin, 2012). Furthermore, another clinical trial entitled “Efficacy of
RAD001/Everolimus in autism and neuropsychological deficits in children with TSC”
is currently recruiting patients to target cognitive functions and autistic behavior
(http://clinicaltrials.gov/show/NCT01730209). In the present study, we illustrate a pa-
tient with TSC, autism, and renal angiomyolipomas, in whom everolimus treatment
was associated with improvement in behavioral deficits in addition to a reduction in
the volume of the kidney tumor.Case presentation
In this study, we illustrate a 27 year-old female patient with TSC, autism, and renal
angiomyolipomas, in whom everolimus treatment was associated with improvement in
behavioral deficits. The patient had a history of cardiac rhabdomyoma since the fetal
period. Eventually, she developed epilepsy (i.e., West syndrome), and multiple skin
lesions, particularly hypomelanic macules, facial angiofibromas, Shagreen patch, scalp
and forehead plaques, and periungual fibromas. Developmental problems were noticed
early during the course of the disease (7-8 months of age). There was maladaptive be-
havior in the kindergarten, impaired social communication, and mental retardation. At
age 15, she showed aggressive behavior, mainly toward her mother. Consequently, she
was admitted in the department of Psychiatry at Osaka University Hospital and diag-
nosed as autism. The patient also had a renal cell carcinoma, which was operated, as
well as bilateral renal angiomyolipomas (n = 8). Genetic analysis revealed TSC1 muta-
tion: TSC1 intron 3 (c.328 + 15A > G).
Two years ago, she took part in an everolimus clinical trial (EXIST-2: ClinicalTrials.gov
number NCT00790400) to assess the efficacy of this drug in TSC. It was a randomized,
double-blind, placebo-controlled study of everolimus (RAD001) (10 mg/day during 18
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department of Dermatology and Psychiatry at Osaka University enrolled in the study, this
was the only patient diagnosed with TSC-related autism. Informed consent was obtained
from the patient and her family. Before enrollment, all patients or parents (if patients had
developmental delays) agreed to write informed consent according to local guidelines.
The ethics committee of Osaka University Hospital approved the protocol for the clinical
trial (EXIST-2: ClinicalTrials.gov number NCT00790400). The safety reviews every 6
months were done by an independent data monitoring committee. This research was
carried out in compliance with the Helsinki Declaration.
The Japanese version of the Aberrant Behavior Checklist (ABC) and the Pervasive
Developmental Disorders - Autism Society Japan Rating Scale (PARS) were used to as-
sess the severity of behavioral deficits. Scores on these scales are shown in Table 1.
Clinical improvement after everolimus treatment was more remarkable for irritability,
stereotypic behavior and inappropriate speech scores on the ABC scale. For instance,
irritability had a 24-point reduction at 6 months of treatment, and completely disap-
peared at endpoint. Inappropriate speech symptoms also disappeared at endpoint. In
addition, stereotypic behavior and lethargy/social withdrawal subscale scores showed an
overall reduction of 10 and 8 points, respectively. The severity of autistic symptoms
measured with the PARS also showed a marked reduction after treatment. The PARS-
present score was reduced in 18 points, which represented a 46.2% improvement in the
severity of behavioral problems at the end of the study. Other TSC signs, particularly
facial angiofibromas and the volume of renal angiomyolipomas also showed a sustained
reduction (Table 1). The EEG was measured during wakefulness, whereas sleep data
were unavailable. There were no abnormal EEG findings before the treatment, showing
8 ~ 9 Hz alpha rhythm at the bilateral parietal and occipital area with no spikes and
slow waves, and no changes after the treatment.Conclusions
This case study shows that everolimus treatment reversed behavioral deficits in a pa-
tient with autism associated with TSC without EEG abnormalities. The improvement
was more remarkable for irritability, stereotypic behavior and inappropriate speech, as
indicated by changes in the respective ABC subscale scores. The severity of autisticTable 1 Response of behavioral symptoms and renal angiomyolipomas to everolimus
treatment
Baseline 6 months 18 months % improvementa
PARS-infant score (0-68) 28
PARS-present score (0-66) 39 32 21 46.15%
ABC Irritability score (0-45) 33 9 0 100%
ABC lethargy/social withdrawal score (0-48) 27 25 19 29.62%
ABC stereotypic behavior score (0-21) 12 0 2 83.33%
ABC hyperactivity score (0-48) 18 15 14 22.22%
ABC inappropriate Speech score (0-12) 2 1 0 100%
AML volume 5.58 4.68 4.06 27.2%
aRelative to baseline. PARS, Pervasive Developmental Disorders - Autism Society Japan Rating Scale; ABC, the Aberrant
Behavior Checklist; AML, angiomyolipoma.
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after everolimus treatment. Although the improvement of autistic features by everoli-
mus is the most striking finding of our study, other manifestations of TSC, including
facial angiofibromas had a notable improvement, as well. Similarly, the volume of renal
angiomyolipomas showed a sustained reduction after everolimus was administered.
In line with a sustained improvement of angiomyolipomas in this study, recent evero-
limus studies have demonstrated the efficacy of this drug in the treatment of some
tumors associated with TSC. An open-label study of five patients with sporadic abdo-
minopelvic and lung lymphangioleiomyomatosis reported a significant shrinkage or
complete resolution of the tumors during a 6-month treatment, although cessation of
everolimus resulted in recurrence of symptoms (Mohammadieh et al, 2013). Larger
open-label studies of everolimus for SEGAs in TSC showed that the treatment was as-
sociated with a marked and sustained tumor reduction (Krueger et al 2010). This was
confirmed by a phase III, randomized, placebo-controlled trial, demonstrating that
everolimus was associated with a SEGA response rate of 35% compared with 0% in the
placebo group. The double-blind, placebo-controlled, phase 3 trial everolimus for
angiomyolipoma in TSC where this patient took part, found an angiomyolipoma re-
sponse rate of 42% for everolimus treatment, which contrasted with a 0% response for
placebo (Bissler et al, 2013). Taken together, these findings demonstrate that some
TSC-related tumors volume can significantly be reduced by everolimus therapy with an
acceptable safety profile.
It is well documented that autism has devastating effects on the patients, their par-
ents and the society, and a symptomatic or etiological treatment is still lacking.
Although this study reports treatment effects on a single patient, to our knowledge, this
is the first study providing evidence that in addition to tumor growth suppression prop-
erties, mTOR inhibition by everolimus in humans might be an effective pharmaco-
logical treatment of ASD associated with TSC. Our findings are consistent with those
of Tsai et al (2012) in animal models, proposing that treatment of TSC1 and TSC2 mu-
tant mice with the mTOR inhibitor rapamycin, prevented both TSC-related cerebellar
pathology and autistic-like behavior. Further support to our results is provided by other
preclinical studies demonstrating that rapamycin reversed deficient social interaction in
mouse models (Sato et al, 2012; Reith et al, 2013). This makes everolimus a promising
drug for the treatment behavior of patients with autism. Our findings warrant further
investigation in future clinical trials (Wang and Doering, 2013).
Cognitive abnormalities in adult mouse models of TSC have also been reported to re-
verse with mTOR inhibitors, even in the absence of neuropathology and seizures
(Ehninger et al. 2008, 2009). This suggests that at least some of the TSC-related cogni-
tive impairments are caused by disinhibited mTOR signaling in adults, and are the
consequence of functional changes rather than irreversible structural defects during de-
velopment (Ehninger and Silva, 2011).The possibility that mTOR inhibitors may have
benefit in the treatment of TSC-brain disease was also highlighted by Meikle et al
(2008) study of a neuronal model of TSC. They found improvement in biochemical and
signaling profiles, reduction in neurofilament expression and phosphorylation, and
markedly improved myelination during rapamycin and everolimus treatment. All to-
gether, these studies support the notion that mTOR inhibition can be the key for an ef-
fective treatment of ASD associated with TSC.
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inhibition in improving behavior and social interaction deficits (Sato et al, 2012; Tsai
et al, 2012; Reith et al, 2013), makes everolimus a promising drug for the treatment of
TSC patients with ASD without EEG abnormalities. These findings warrant further
investigation with physiological assessments in future clinical trials of mTOR inhibi-
tors in autism.
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